Hybrid closed-loop insulin delivery systems have become the standard of care to manage type 1 diabetes.1 These systems apply glucose-responsive insulin delivery improving glycemic outcomes including increasing time in range without increasing the risk of hypoglycemia, and improving quality of life.2 A limiting factor of automated insulin delivery systems is the relatively slow absorption of rapid-acting insulin analogs, which leads to less effective glucose lowering and greater glycemic fluctuations.3 This evidence concerns the gene INS and type 1 diabetes mellitus.